Arbor Biotechnologies

Cambridge, MA · Founded 2016 · Privately Held (backing)

Developer of genomic tools designed to improve human health and sustainability. Arbor Biotechnologies is based in Cambridge, MA and was founded in 2016. It was valued at $239 million at its later-stage round in Oct 2025, the last priced event on record. It has raised $305 million across 2 recorded rounds; the latest was a $215 million later-stage round in Oct 2021.

PMV mark · valuation
$238.9M
Oct 2026
Priced at
its later-stage round
Oct 2025
Total raised
$304.5M
Last round
Later Stage VC
Oct 2021

Who backs Arbor Biotechnologies?

31 investors
InvestorType
Temasek HoldingsOther
Samsung Venture InvestmentOther
Alexandria Venture InvestmentsOther
ARCH Venture PartnersVenture capital
Qatar Investment AuthorityAsset manager
T. Rowe Price Group—
S32Venture capital
Partners InvestmentVenture capital
GreatPoint VenturesVenture capital
Logos CapitalHedge fund
+ 21 more investors · a free account shows the complete list
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

Arbor Biotechnologies investors

31 investors are on record for Arbor Biotechnologies, including Temasek Holdings, Samsung Venture Investment, Alexandria Venture Investments and ARCH Venture Partners. By type, the record holds 9 venture capital firms and 3 hedge funds. The later-stage round in Oct 2021 drew 37 investors.

Free account
More of Arbor Biotechnologies with a free account
  • ·The complete investor list: 31 names
  • ·Watch Arbor Biotechnologies: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 31 firms already write checks for companies like Arbor Biotechnologies. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View